Waters Corporation

1. Prognoza ↑

   The company raised 2026 revenue guidance for Biosciences and Diagnostic Solutions by $10 million to a new target of approximately $3.045 billion.

   Cytat ze źródła

   “We now expect Biosciences and Diagnostic Solutions to deliver approximately $3.045 billion of reported revenue in 2026, raising our prior guidance by $10 million, which reflects an underlying...”

2. Prognoza

   WAT expects instrument outfitting to drive a revenue tailwind for its Analytical Sciences division over the next 3 to 5 years.

   Cytat ze źródła

   “Weighing the focus, modality and analytical intensity of each site, we expect instrument outfitting to drive a revenue tailwind for our Analytical Sciences division over the next 3 to 5 years.”

3. Liczba

   Total company as reported revenue was USD 1.645 billion in the second quarter, which included $828 million of organic revenue.

   Cytat ze źródła

   “In the second quarter, total company as reported revenue was USD 1.645 billion, comprising of $828 million of organic revenue...”

4. Słabnie

   WAT raised its full year 2026 organic constant currency revenue guidance to 6.5% to 8% due to strong first quarter performance and the instrument replacement cycle.

   Cytat ze źródła

   “We have begun 2026 with significant momentum, driven by the instrument replacement cycle, idiosyncratic dose drivers and accretion from our high-growth... Turning now to 2026 guidance and our value creation road map. As a result, we are raising our full year 2026 organic constant currency revenue guidance to 6.5% to 8%, reflecting our strong first quarter performance and embedding $15 million of expected...”

Management sounded noticeably less positive answering analysts than in its prepared script — a bigger drop than in 95% of calls. Scripts are polished in advance; a drop under questioning often marks the topics analysts pressed on, so the answers deserve a closer read than the script.